Objective To evaluate the clinical effectiveness of Periocline (2% minocycline hydrochloride ointment) versus Yakang (metronidazole stilus) for treating chronic periodontitis in adults by means of meta-analysis. Methods The following electronic databases as PubMed, The Cochrane Library, EMbase, CNKI, CBM and WanFang Data were searched on computer from inception to July, 2012, and the references of all selected studies were also retrieved to collect the relevant randomized controlled trials (RCTs) on periocline vs. Yakang for chronic periodontitis. According to the inclusion and exclusion criteria, two reviewers independently screened studies, extracted data, and evaluated the methodological quality of the included RCTs. Then meta-analysis was performed using RevMan 5.0 software. Results A total of 7 RCTs involving 737 patients were included. The results of meta-analysis showed that there were no significant differences in probing depth (MD=0.26, 95%CI −0.35 to 0.87, P=0.40), clinical attachment level (MD=−0.10, 95%CI −0.75 to 0.54, P=0.75), sulcus bleeding index (MD=0.12, 95%CI −0.30 to 0.53, P=0.59), and plaque index (MD=0.07, 95%CI −0.09 to 0.22, P=0.41) between the Periocline group and the Yakang group. Conclusion The current evidence shows that based on periodental non-surgical treatment, Periocline is similar to Yakang in improving the symptoms of chronic periodontitis in adults. However, given the low methodological quality and the limited sample size of most included studies, this conclusion still needs to be further proved by conducting more strictly-designed, high-quality and large-scale RCTs. The long-term effectiveness of those 2 treatment modalities also needs to be observed in a longer follow-up duration.
Objective To explore the relationship between periodontitis and postmenopausal osteoporosis.Methods Databases were electronically searched from PubMed (1966 to December, 2010), EMbase (1974 to December, 2010), CBM (1978 to December, 2010), VIP (1989 to December, 2010), CNKI (1979 to December, 2010) and WanFang Data (January, 2007 to December, 2010), and the references listed in all papers were also retrieved. The literature was screened according to the inclusion and exclusion criteria by two reviewers independently; the methodology quality was evaluated after data abstraction; and then the RevMan 5.0 software was used for meta-analyses. Results Four trials were included. Among the total 678 patients involved, 263 were postmenopausal osteoporosis patients, while the other 415 were non-osteoporosis patients. The results of meta-analyses showed that: a) Clinical attachment loss (CAL) of the postmenopausal osteoporosis patients was significantly higher than that of the non-osteoporosis patients (WMD=0.60, 95%CI 0.23 to 0.96); b) The level of gingival recession of the postmenopausal osteoporosis patients was significantly higher than that of the non-osteoporosis patients (WMD=0.78, 95%CI 0.41 to 1.14); c) There were no significant differences in plaque index (PI), gingival index (GI) and periodontal probing depth (PPD) between the two groups (WMD=0.17, 95%CI 0.00 to 0.35; WMD=0.05, 95%CI –0.09 to 0.19; and WMD=–0.08, 95%CI –0.24 to 0.09); d) The results of one study indicated that the rate of periodontitis in the postmenopausal osteoporosis patients was higher than that of the non-osteoporosis patients (OR=2.45, 95%CI 1.38 to 4.34, Plt;0.01); the severe alveolar crest height loss was related to osteoporosis (OR=4.20, 95%CI 1.57 to 11.22, Plt;0.01). Conclusion Postmenopausal osteoporosis patients are more prone to suffer from periodontitis or turn to the worse stage of periodontitis. In consideration of the factors such as small scales and incomplete measure indexes of the included studies, which have influences on the intensity and comprehensiveness of this conclusion, more high-quality studies are required.
Objective To assess the effectiveness of local delivery of metronidazole as an adjunct to scaling and root planing (SRP) versus SRP alone in patients with chronic periodontitis. Methods We searched six major electronic databases including CNKI, PubMed, EBSCO, OVID, ScienceDirect, and Springrlink from establishment to May 2009. Randomized controlled trials (RCTs) comparing metronidazole plus SRP with SRP alone for at least 1 month of follow-up were included. The methodological quality of included trials was assessed by the method recommended by the Cochrane Collaboration and pooled analysis was conducted using Stata 10.0 software. Results Seven RCTs met the inclusion and exclusion criteria. A significant mean reduction in probing depth with WMD –0.43 and 95%CI –0.72 to –0.13 for the combined metronidazole and SRP was observed, but there were no statistical significant differences at the clinical attachment level between the two treatments with WMD –0.23 and 95%CI –0.53 to 0.06. Conclusion Metronidazole as an adjunct to SRP could reduce probing depth in the treatment of chronic adult periodontitis.
Objective To assess the effectiveness and safety of tinidazole buccal tablets produced by China Associate Pharmaceutical Co. , Ltd. on periodontitis and pericoronitis. Methods A mukicenter randomized controlled doubleblind trial was designed. Three units from Shanghai, Hangzhou and Chengdu joined the study. The trial tablet oftinidazole was supplied by the mentioned Pharmaceuticals company. A marketed tinidazole produced by Zhejiang Hacon Marine BioPharmaceutical Co. Ltd. , was used as positive control. Both drugs were administered at a dose of 5 mg four times daily for 6 days. Outcomes measurement included symptoms, clinical signs of the patients with periodontitis or pericoronitis, and gingival index （GI）, bleeding index （BI）, plaque index （PI） and periodontal depth （PD） were measured for the patients with periodontitis. Subgingival bacterial samples taken from subgingival plaque of diseased teeth of the cases with periodontitis or from exudates of diseased wisdom teeth of the cases with pericoronitis were cultivated aerobically and anaerobically. Putative microorganisms were isolated and colony forming unit （CFU） were counted before and after treatments. All adverse drug reactions （ADIL） were observed, recorded, properly treated and followed. Results Altogether, 157 cases met the inclusion criteria and entered the study. Lost to follow-up happened in 14 cases with drop-out rate of 8.9%. In per-protocal cases there were 109 with periodontitis （57 in trial group and 52 in control group） and 34 with pericoronitis （17 in trial group and 17 in control group）. Basehne analysis demonstrated that the two groups were comparable. At the final examination, it was found that 85% of the cases in the periodontitis group showed significant）mprovement gingival bleeding, both gingival pain and biting pain subsided, PD, BI, GI and PI reduced with no significant difference between trial and control groups （P 〉0.05）. The symptoms of sixty percent of cases with pericoronitis were improved. More than 75% of the cases with pericoronal pus, the pus were ehminated. Over 60% of the cases with lymphadenitis, the node swelling was subsided. Mouth opening increased in all cases with pericoronitis. All improvements in the cases with pericoronitis showed no significant difference between trial and control groups （ P 〉0.05 ）. The effective rate only including cured and markedly improved cases reached 88.2% in both groups of pericoronitis. Various species of putative microorganisms were detected in patients with periodontitis or pericoronitis before treatment. A great proportion of the putative microorganisms eliminated or the quantity reduced after treatment, with no significant difference between trial and control groups （P 〉0.05 ）. Candida albicans was not detected before and after treatment. Nine patients developed ADRs, 5 （6.8% ）in trial group and 4 （5.8% ）in control group. All the ADRs were mild and transient, not interfering with drug administration. Conclusions This study showed the tinidozole buccal tablet with commercial name “Jinhe” supphed by China Associate Pharmaceutical Co. , Ltd. do inhibit the common putative microorganisms of periodontitis and pericoronitits, and do not influence balance of the local commensal microganisms. It reduces severity of the infectious inflammation and benefits improvement and/ or rehabilitation of periodontitis and pericoronitis, with only mild and transient ADRs. The trial and control tablets have similar efficacy and safety for patients with periodontits or pericoronitis.
Objective To systematically review the relationship between periodontal disease and gastric cancer risk. Methods We retrieved PubMed, EMbase, CNKI, WanFang Data, VIP, and CBM databases to collect studies about the correlation between periodontal disease and gastric cancer from inception to January 31st, 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Results Five studies were included. The results of meta-analysis showed that there was no significant correlation between periodontal disease and gastric cancer (RR=0.99, 95%CI 0.83 to 1.19, P=0.93). Sensitivity analysis showed good stability. Subgroup analysis showed that the type of study, race and type of effect size have no statistically impact on the outcome, there was no significant correlation between periodontal disease and gastric cancer. Conclusion According to the current evidence, periodontal disease probably is not a risk factor of gastric cancer. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.
Prostate disease is one of the most common urological disease. A large number of studies have shown that prostate disease is related to changes in the local microenvironment. Periodontitis is a chronic inflammatory disease characterized by the destruction of periodontal tissue caused by a variety of pathogenic microorganisms. Its pathogenesis may involve many factors. Periodontitis may have adverse effects on cardiovascular, respiratory, digestive and endocrine systems. Recent studies have found that chronic periodontitis is associated with the occurrence and development of benign prostatic hyperplasia and prostatitis, but the relationship is not clear. Therefore, further research is needed. This article elaborates on inflammation and benign prostatic hyperplasia and prostatitis, periodontitis and prostatitis, and periodontitis and benign prostatic hyperplasia, aiming to provide certain ideas for clinical research and diagnosis and treatment.